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Purpose: Poly lactic-co-glycolic acid nanoparticles (PLGA-NP) are widely used as a 
biodegradable biomaterial in medicine. Rapamycin-eluting stents have been used for prevention 
of restenosis during surgery. This study investigated the effect of pretreatment with intraluminal 
perfusion of carbopol-encapsulated rapamycin-loaded PLGA nanoparticles (RAP-PLGA-NP) 
on neointimal hyperplasia in a rabbit vein graft model.
Methods: A segment of common carotid artery was replaced with a segment of external 
jugular vein in 60 rabbits which were then separated into four treatment groups, ie, Group 1, 
in which vein grafts were pretreated with intraluminal RAP-PLGA-NP perfusion, Group 2 in 
which vein grafts underwent equivalent empty vehicle (PLGA-NP) perfusion, Group 3, in 
which vein grafts received no treatment, and Group 4, which served as a sham operation group 
receiving normal vein contrast. On postoperative day 28, the grafts and normal veins were 
harvested for histologic examination, flow cytometry analysis, and high-performance liquid 
chromatography measurement.
Results: Compared with Group 1, the intima of the grafts were thickened, the ratio of intimal 
area to vessel area increased, and the collagen volume index of the vein grafts increased 
significantly in Groups 2 and 3. The cell proliferation index in Group 1 (21.11 ± 3.15%) was 
much lower than that in Group 2 (30.35 ± 2.69%) and in Group 3 (33.86 ± 8.72%). By high-
performance liquid chromatography measurement, retention of rapamycin was detected in 
Group 1 (11.2 ± 0.37 µg/10 mg) 28 days after single drug perfusion.
Conclusion: Pretreatment with intraluminal RAP-PLGA-NP perfusion may inhibit neointimal 
hyperplasia in vein grafts by penetrating into local tissue and limiting cell proliferation.
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Introduction
Autologous saphenous vein grafting has been a cornerstone in coronary surgery for 
almost four decades.1 However, stenosis or occlusion of the vein graft remains high, 
occurring in up to 15% of cases in the first postoperative year, and increasing up to 50% 
after 10 years.1,2 Stenosis of the graft results from a combination of factors, including 
the intrinsic quality of the vein, collection and preservation techniques,3 hemodynamic 
alteration after grafting, and inflammation and remodeling of the vein. Updated 
therapeutic strategies to alleviate restenosis or neointimal hyperplasia correspondingly 
have included collection and preservation of the vein, pharmacotherapy, gene therapy, 
radiotherapy, and laser and photodynamic therapy.4,5 These treatments have shown 
inhibitory effects on restenosis in animal trials, but still have some drawbacks.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Rapamycin is a novel macrolide antibiotic with marked 
antiproliferative properties. Both experimental and clinical 
studies have demonstrated its potency in reducing stenosis 
in stents and grafts by suppressing neointimal hyperplasia.6–8 
However, some reports have indicated that inhibition of 
neointimal formation leads to incomplete neointimal cover-
age associated with a high rate of thrombus formation after 
stenting.9–11 Subacute thrombosis might be caused by delayed 
recovery of the intima and a hypersensitivity response to 
the drug stent.11–13 Therefore, continued efforts to improve 
polymer biocompatibility are warranted.
In recent years, biodegradable nanoparticles and 
bioadhesive polymer-coated vehicles have attracted consid-
erable interest for the prevention of restenosis in vascular 
graft disease and hold promise to solve problems produced 
by local drug delivery. Poly lactide-co-glycolide (PLGA) 
has been approved by the US Food and Drug Administra-
tion (FDA) as a biocompatible and biodegradable polymer 
for clinical application, and has been used extensively in 
the manufacture of nanoparticles.14,15 Carbopol is a good 
bioadhesive agent, reported to be a promising stabilizer for 
fabrication of nanoparticles,16 and exhibits good retention 
both in vitro and in vivo.15,17 Local delivery of a drug-loaded 
bioadhesive agent improves inhibition of restenosis mainly 
due to the bioadhesive surface, good biocompatibility, easy 
penetration into the vascular wall, and sustained-release capa-
bility. Rapamycin encapsulated with several surface-active 
agents has demonstrated good antiproliferative efficacy in 
vascular transplantation when locally applied.18–20 However, 
external application of antiproliferative drugs to the vessel 
is suspected to affect ambient normal tissues. The ideal route 
of administration needs to be explored.
Guzman et al21 demonstrated that retention or absorption 
of drugs loaded into PLGA nanoparticles in the arterial wall 
could be detected after a short, single intraluminal infusion 
14 days earlier in an artery injury model. On the basis of 
a catheter delivery system, uptake of rapamycin-PLGA 
nanoparticles in the artery was also shown by Miao et al.22 
However, little information was given on the effect of local 
luminal administration of rapamycin nanoparticles in the 
vein graft. We hypothesized that pretreatment with carbopol-
encapsulated, rapamycin-loaded PLGA nanoparticles (RAP-
PLGA-NP) by local intravenous perfusion could play a role in 
penetrating the vessel from the inner wall without contaminat-
ing the tissue outside. In this study, the vein was pretreated 
with RAP-PLGA-NP ex vivo and then moved into a rabbit 
vein graft model to test this hypothesis in order to open a new 
avenue for prevention of restenosis after vein grafting.
Materials and methods
Animal model
New Zealand albino rabbits weighing 2.6 ± 0.3 kg were 
obtained from the Laboratory Animal Center of Shandong 
University. Animals received humane care, and the experi-
ments were performed in accordance with the guidelines 
of the Animal Care and Use Committee of Shandong 
University. After intramuscular injection of ketamine 2 mg/kg, 
stable anesthesia was maintained by continuous infusion 
of pentobarbital administered through the ear vein at a rate 
of 200 µg/kg/min. The external jugular vein and common 
carotid artery on the same side were isolated (about 4 cm in 
length). Heparin sodium 125 U/kg was injected intravenously 
after the vessels were freed, and a segment of vein about 
3 cm in length was resected. The common carotid artery was 
clamped proximally and distally to the planned anastomosis 
with two bulldog clips. Both ends of the prepared external 
jugular vein were anastomosed end-to-side into the common 
carotid artery with 7–0 Prolene. Once the anastomosis was 
completed, the original common carotid artery between the 
two anastomotic ends (about 3 cm in length) was ligated 
and resected. The bulldog clips were removed, and the vein 
graft filled with arterial blood immediately (Figure 1A). 
Intravenous penicillin G procaine (0.5 million units) was 
administered during surgery and daily for three days post-
operatively. The rabbits were fed aspirin 2 mg/kg/day for 
anticoagulation from the second postoperative day until the 
end of the study. All the operations were performed by the 
same two surgeons.
Preparation of rAP-PLgA-NP
Rapamycin and other chemicals used in this study were 
provided by Shandong Medical Institution, China, and used 
without any further purification. Carbopol 940 was purchased 
from the People’s Pharmaceutical Factory of Shanghai, 
China. RAP-PLGA-NP was prepared by the School of Phar-
macology at Shandong University according to previously 
Figure 1 A) rabbit model of interposition of external jugular vein into the common 
carotid artery using an end-to-side technique. B) self-made drug-perfusion device.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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described methods.23 The copolymer was composed of 
rapamycin and PLGA, and the ratio of rapamycin to PLGA 
was 0.5:1 (w/w). Finally, the copolymer was encapsulated 
with carbopol 940, and the concentration of carbopol in the 
compound was 0.1% (w/v).
Definition of groups
The animals were separated into four groups, ie, Group 1 
(n = 15) in which the vein grafts were treated with RAP-
PLGA-NP by local intraluminal perfusion (500 µg/mL, 
pressure 60 mmHg) for 180 seconds using a drug infusion 
device before grafting (Figure 1B), Group 2 (n = 15) in which 
the vein grafts were pretreated with intraluminal perfusion 
of an empty vehicle (PLGA-NP) with the same pressure 
and time as used in Group 1, Group 3 (n = 15) in which the 
vein grafts were untreated, and Group 4 (n = 15) in which 
isolation of the carotid artery and external jugular vein was 
performed without grafting.
Animals were sacrificed on postoperative day 28 by 
pentobarbital overdose, after 10 mL of blood was drawn. 
Grafts were fixed using 4% phosphate-buffered formaldehyde 
via puncture of the left ventricle and the incision of the right 
atrium. The vein grafts and normal veins were then harvested 
and fixed in 4% polyformaldehyde for histopathologic exami-
nation. During harvesting, the anastomosis was avoided in 
the proximal and distal segments of the collected grafts in 
order to exclude any influence of the anastomosis. Veins were 
collected without fixation for flow cytometry analysis and 
high-performance liquid chromatography measurement.
To assess absorption of RAP-PLGA-NP in local vein 
grafts, a further 40 rabbits were pretreated with high-dose 
(500 µg/mL, n = 20) or low-dose (100 µg/mL, n = 20) intra-
venous RAP-PLGA-NP perfusion during operation. On post-
operative days 7, 14, 21, and 28, five rabbits from each group 
were sacrificed to test plasma levels and retention of drug in 
local tissue using high-performance liquid chromatography.
histopathologic analysis
The fixed veins were dehydrated using graded alcohols 
and embedded in paraffin. Slice of 5 µm was cut from the 
proximal, middle, and distal segments of the vein, respec-
tively, and stained with hematoxilyn and eosin and Masson 
stain. The cross-section of the graft was divided into four 
quadrants. Three measurements were made in each quadrant, 
and the median value of all measurements in each cross-
section was regarded as the thickness of intima. Because the 
adventitial area was difficult to distinguish due to adhesion 
to the surrounding tissue, the intima area (IA) and media area 
were measured as vessel area (VA). Ratio of intima area to 
vessel area (IA:VA) was calculated. Collagen volume index 
(CVI) was represented by means of the ratio of collagen 
area to the vein wall area on Masson stain slices. The intimal 
thickness, IA:VA, and CVI of the veins were measured and 
analyzed using the Pro-Plus 6.0 image system (Media Cyber-
netics, Inc., Bethseda, MD). All slices were investigated by an 
experienced pathologist who was blinded to the experimental 
design. A mean value of measurements was regarded as the 
representative results of each group.
Flow cytometry assay
The adventitia of the grafts and normal veins were removed 
carefully and cut longitudinally. The specimens were washed 
twice with phosphate-buffered saline and were made into a 
homogenate. Tissue homogenate were digested by 0.25% 
trypsin for 10 minutes and filtered via 75 µm mesh to 
get single cells. The cells were then fixed with precooled 
ethanol 75% at 4°C overnight. After being washed twice, 
the cells were loaded with propidium iodide (65 µg/mL, pH 
7.4; Sigma, St. Louis, MO) containing RNase A (50 µg/mL 
in Triscl, pH 7.4; Sigma) for 30 minutes in darkness at room 
temperature. Each sample containing about 1 × 106 cells was 
collected. The data were obtained by BD Cellquest software 
(Becton Dickinson and Company, Franklin Lakes, NJ) and 
the cell cycle was analyzed by ModFit software (Verity 
Software House, Topsham, ME). The proliferation index (PI) 
was represented by the ratio of the S + G2M phase to G0G1 
phase (PI = (S + G2M)/GoG1).
Measurement of rapamycin uptake in vivo 
and concentration in plasma
To determine whether rapamycin was retained in the vein 
graft 28 days after the single short perfusion, the samples 
were measured using a high-performance liquid chromatog-
raphy method described previously.23 Retention of drug in 
the samples was expressed as the content of rapamycin (µg) 
per 10 mg tissue. Measurement of one sample was repeated 
three times and the mean value represented as the ultimate 
result. To test the rapamycin concentration in plasma, 500 µL 
plasma mixed with 10% trichloroacetic acid (200 µL) and 
1 mL distilled water was centrifuged for 10 minutes at 1500 
rpm, and 500 µL of the supernatant was analyzed according 
to the standard curve.
statistical analysis
SPSS 10.0 for Windows (SPSS Inc, Chicago, IL) was used 
for the statistical analysis. Variables were presented as International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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mean ± standard deviation. One-way analysis of variance 
with a post hoc least significant difference test was used. 
Comparisons between the two groups were done by t-test. 
P , 0.05 was considered to be statistically significant.
Results
Two rabbits, one each in Groups 2 and 3, respectively, 
were excluded from the study because vein graft throm-
bus occlusion was detected. One rabbit in the high-dose 
group died due to an anesthetic accident and one rabbit 
in the low-dose group was found to have thrombosis on 
postoperative day 3. No other complications, such as 
aneurysmal degeneration or plaque, were observed in any 
of the animals.
histologic examination
Representative photographs of hematoxilyn and eosin and 
Masson staining are shown in Figures 2 and 3. In Groups 
2 and 3, more cells were aggregated at the intima than in 
Group 1. This might be explained by the antiproliferative 
effect of RAP-PLGA-NP on neointimal formation. On 
postoperative day 28, the intima of grafts were thickened 
(Figure 4A), and the IA:VA and CVI of the veins were 
increased significantly (Figure 4B) in Group 2 (n = 7) and 
Figure 2 histopathologic examination of vein grafts and normal vein with hematoxylin 
and eosin stain 28 days after operation (original magnification 200×). Bar = 100 µm. 
A) group 1 (rapamycin-loaded PLgA nanoparticle vein graft perfusion), B) group 2 
(empty vehicle), C) group 3 (vein graft with no treatment), and D) group 4 (sham 
operation, normal vein).
Abbreviation: PgLA, poly lactic-co-glycolic acid.
Figure 3 Pathologic examination of vein grafts and normal veins with Masson stain 
(original magnification 200×). A) group 1 (rapamycin-loaded PLgA nanoparticle 
vein graft perfusion), B) group 2 (empty vehicle), C) group 3 (vein graft with no 
treatment), and D) group 4 (sham operation, normal vein). In these figures, the 
collagen was dyed to red. Bar = 100 µm.
Abbreviation: PgLA, poly lactic-co-glycolic acid.
Group 3 (n = 7) compared with Group 1 (n = 8). Signifi-
cant differences in intimal thickness and IA:VA were also 
found between Group 1 and Group 4 (n = 8), but there 
was a remarkable reduction in graft hyperplasia in Group 
1 compared with Groups 2 and 3. There was no significant 
difference between Group 2 and Group 3 for intimal thick-
ness, IA:VA, and CVI of the grafts. These results indicate 
that empty vehicle-PLGA-NP had no effect on intimal 
hyperplasia. Compared with images B and C in Figure 2, 
we could extrapolate that only PLGA-NP did not induce 
inflammation in the intima 28 days after the perfusion.
Flow cytometry analysis
The cell cycles of vein grafts in Groups 1 and 4 were almost 
stationary at the G0G1 phase (Figure 5). In Groups 2 and 3, 
cells in the DNA synthesis phase were significantly increased 
compared with Groups 1 and 4. The PI in Group 1 (n = 4) 
was much lower than that in Group 2 (n = 4, 21.11 ± 3.15% 
versus 30.35 ± 2.69%, P , 0.01) and Group 3 (n = 4, 
21.11 ± 3.15% versus 33.86 ± 8.72%, P , 0.01). Even 
though the PI of Group 1 was lower than that of Groups 2 
and 3, it was higher than that in Group 4 (21.11 ± 3.15% 
versus 10.99 ± 2.01%, P , 0.05). There was no significant 
difference in the PI between Groups 2 and 3 (30.35 ± 2.69% 
versus 33.86 ± 8.72%, P = 0.477).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 4 A) Intimal thickness of vein grafts and normal veins on postoperative 
day 28. *P , 0.05 compared with group 4 and †P , 0.05 compared with group 1. 
B) ratio of intimal area to vessel area and collagen volume index in the four groups. 
*P , 0.05 compared with group 3 and †P , 0.05 compared with group 1. Data are 
expressed as mean ± standard deviation. C) retention of rapamycin-loaded PLgA 
nanoparticles in the local vein graft at different doses. Differences between the two 
groups existed from seven to 28 days after treatment (P , 0.01).
Abbreviations: IA:VA, ratio of intimal area to vessel area; cVI, collagen volume 
index; PgLA, poly lactic-co-glycolic acid.
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in the low-dose group by high-performance liquid chroma-
tography. At the same postoperative time points, there was 
no statistically significant difference in plasma concentra-
tions of rapamycin between these two groups (low-dose 
versus high-dose 1.51 ± 0.12 versus 1.69 ± 0.09 ng/mL, 
0.67 ± 0.07 versus 0.54 ± 0.11 ng/mL, and 0.32 ± 0.05 
versus 0.41 ± 0.04 ng/mL on postoperative days 7, 14, 
and 21, respectively). Retention or uptake of rapamycin in 
local tissues is shown in Figure 4C. Differences between 
the low-dose and high-dose groups persisted from days 
7 to 28 (P , 0.01). On day 14 after implantation, drug 
uptake in local tissue peaked and then decreased gradually. 
Residual rapamycin in the vein graft could be measured in 
both groups even on postoperative day 28. Liver function 
was estimated by aspartate aminotransferase and alanine 
transaminase, and kidney function was represented by blood 
urea nitrogen and creatinine clearance rate, which were also 
tested at different time points. No abnormality was observed 
between the normal animals and the animals treated with 
RAP-PLGA-NP (data not shown).
Retention of rapamycin in local vein grafts was 
detected 28 days after the single intraluminal perfusion 
only in Group 1. The concentration of drug was 11.2 ± 
0.37 µg/10 mg in the local vein graft (n = 3). No rapamy-
cin was detected in the other three groups (n = 3 in each). 
No rapamycin was detected in plasma after 28 days in any 
of the groups.
Discussion
In this study, we investigated the effect of pretreatment 
with rapamycin nanoparticles by local luminal perfusion 
on vein graft stenosis. Intravenous perfusion with carbopol-
  encapsulated RAP-PLGA-NP in vivo before grafting 
could suppress neointimal hyperplasia in a rabbit vein 
graft model. These results reflect more local penetration of 
rapamycin nanoparticles into the venous wall to inhibit cell 
proliferation.
Rapamycin was shown to have a novel pharmacologic 
effect on prevention of vascular stenosis by blocking cell 
cycle progression from the G1 phase to the DNA synthesis 
phase.24 This mechanism could be the result of a combination 
of rapamycin and its specific intracellular receptor, FK506 
binding protein 12 (FKBP 12), leading to inactivation of the 
mammalian target of rapamycin (mTOR), which inhibits the 
transcription of related genes and DNA synthesis, and subse-
quently limiting the proliferation and migration of vascular 
smooth muscle cells.25 Both ex vivo and in vivo investiga-
tions have confirmed the relationship between mTOR and 
Measurement of rapamycin by high-
performance liquid chromatography
Plasma levels of rapamycin were significantly lower than 
those in vein tissues in both the high-dose group and 
low-dose group (P , 0.01). On postoperative day 28, 
rapamycin was detected neither in the high-dose group nor International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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rapamycin in neointimal proliferation.26,27 During coronary 
artery bypass surgery, the saphenous vein graft was always 
preserved in heparinized saline before grafting. Meanwhile, 
the vein graft could be pretreated with intraluminal RAP-
PLGA-NP perfusion to prevent future formation of neointi-
mal hyperplasia.
PLGA-NP could prolong drug retention time in tissues 
and release at a constant velocity to improve drug bioavail-
ability.21 Some drugs, including therapeutic antisense, have 
been loaded into PLGA-NP to prevent or inhibit restenosis 
in experimental models.28–30 In our preliminary study, we 
found that carbopol 940 was a good carrier, and the release 
curve of carbopol-encapsulated RAP-PLGA-NP ex vitro fits 
the Higuchi model.23 The present study showed that local 
intravascular perfusion with RAP-PLGA-NP before graft-
ing had good biocompatibility. After ex vivo treatment, drug 
retention was also confirmed in local tissue on postoperative 
day 28. The dose of RAP-PLGA-NP selected was based on 
preliminary testing. The vein grafts treated with a high dose 
of drug showed less neointimal hyperplasia than grafts treated 
with a low dose (data not shown). When the vein grafts were 
pretreated with rapamycin, the perfusion pressure was limited 
to 60 mmHg and duration to 180 seconds to allow rapamycin 
to penetrate into the vein. The infusion device was designed 
by imitating pressure monitoring during cardiopulmonary 
bypass. We found the perfusion speed and pressure could be 
controlled very well during intraluminal perfusion ex vivo.23 
The materials were easily obtained, and the procedure was 
simple, without any wasting of time. Furthermore, absorption 
of rapamycin into the graft was detected without retention of 
the drug in plasma, as measured by high-performance liquid 
chromatography in the RAP-PLGA-NP perfusion group on 
postoperative day 28.
The results of our study showed that intimal thick-
ness, IA:VA, and CVI of the grafts in the RAP-PLGA-NP 
intraluminal perfusion group were less increased than that 
in the grafts pretreated with empty vehicle perfusion or 
without treatment. Thus, we believe that the effects of RAP-
PLGA-NP on suppression of neointimal hyperplasia were 
due to direct infiltration into the local target tissue.
Drug retention in the local vein graft measured by high-
performance liquid chromatography at different time points 
suggested that the rapamycin could release consistently 
in vivo after a short, single perfusion before grafting. The 
higher retention of drug in local tissue than that in Miao’s 
study might be attributable to the different route of drug 
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Figure 5 The flow cytometry assay for the proliferation cycles of the cells in the vein grafts and the normal vein. A) group 1 (rapamycin-loaded PLgA nanoparticle vein graft 
perfusion), B) group 2 (empty vehicle), C) group 3 (vein graft with no treatment), and D) group 4 (sham operation, normal vein). s phase, DNA synthesis phase.
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administration.22 In our study, the vein graft was pretreated 
with RAP-PLGA-NP ex vivo and was then implanted in vivo, 
whereas in the study by Miao et al22 the drug was delivered 
by catheter directly to the target tissue under blood flow. No 
rapamycin was measured in plasma on postoperative day 
28. Liver and kidney function were not damaged in the low-
dose and high-dose treatment groups. This suggested that 
slow release of the drug and low blood levels of rapamycin 
make systemic toxicity unlikely. Moreover, no thrombosis or 
aneurysm occurred following treatment with RAP-PLGA-NP, 
which was in accordance with other studies.18–20,31 The 
early thrombus occurring in some of the animals in our 
study might have been caused by manipulation rather than 
being an adverse effect of the drug. Previous studies have 
indicated that the efficacy of rapamycin in stents might not 
persist for a long time period.31,32 It has been suggested 
that even though retention of the drug could be detected 
at day 90, intimal proliferation could not be inhibited any 
further at this time point.32 Therefore, the duration of effect 
of rapamycin in local tissue in vivo after ex vivo treatment 
needs further investigation. Furthermore, the effect of empty 
PLGA-NPs in vivo and the most effective dose of RAP-
PLGA-NP should also be explored, because local toxicity 
and any adverse effects or complications would influence 
clinical applicability.11
Previous reports have suggested that rapamycin could 
reduce proliferation of smooth muscle cells by interfering 
with DNA synthesis,25and therefore PI was selected as 
an indicator to evaluate the antiproliferative efficacy of 
rapamycin. In preparation of the cell sample, the adventi-
tia was removed to exclude interference from fibroblasts 
in the adventitia. This guarantees that the results of flow 
cytometry analysis which precisely represented cell status 
in the intima and media. These results indicate that pre-
treatment with RAP-PLGA-NP could decrease neointimal 
hyperplasia of vein grafts by limiting cells at the latency 
stage. In histologic slices, fewer cells were found in the 
intima in the rapamycin treatment group than in the vehicle 
or blank groups, which was coincident with the result of 
flow cytometry analysis. Proliferation was higher in the 
intraluminal RAP-PLGA-NP perfusion group than that in 
the normal vein group, but it was much lower than that in the 
graft without any treatment group. The difference between 
the intraluminal RAP-PLGA-NP perfusion group and the 
normal vein might be caused by manipulation and alteration 
in the hemodynamics of the graft. In fact, proportionate 
proliferation of intima in vein grafts is desirable in clinical 
practice after implantation.
The limitation of the current investigation was use of the 
PI alone as the indicator of cell proliferation, which indirectly 
reflected neointimal hyperplasia in the grafts. In addition, 
longer follow-up of the efficacy of RAP-PLGA-NP will be 
undertaken in future research, and only PLGA-NP will be 
used in vein grafts in further studies.
Conclusion
Pretreatment with RAP-PLGA-NP intraluminal perfusion could 
inhibit intimal hyperplasia in a rabbit model of autologous 
vein grafting. Local administration of rapamycin nanoparticles 
mainly limits the cell cycle by inhibiting cell proliferation in 
tissues in situ. Pretreatment with RAP-PLGA-NP intravascular 
perfusion would be a potential therapy in vein graft disease.
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